Navigation Links
Naturally-occuring protein may be effective in limiting heart attack injury and restoring function
Date:5/6/2008

Medical College of Wisconsin researchers in Milwaukee have shown for the first time that thrombopoietin (TPO), a naturally occurring protein being developed as a pharmaceutical to increase platelet count in cancer patients during chemotherapy, can also protect the heart against injury during a heart attack.

The study, led by John E. Baker PhD, professor of pediatric surgery in the division of cardiothoracic surgery, was published in the January 2008 issue of Cardiovascular Research. The importance of these findings was underscored in an accompanying editorial.

Currently there are no therapies available to directly protect the heart against the damaging effects of a heart attack. Dr. Bakers team has shown that administering a single dose of TPO to rats during a heart attack decreased the extent of permanent muscle damage to the heart and increased the ability of the heart to function afterwards, when compared with no drug treatment. Additionally, they found that a single cardioprotective treatment with TPO did not increase platelet count. This novel finding suggests the cardioprotective actions of TPO are separate from its ability to increase platelet count.

Dr. Baker has submitted a US and worldwide patent application on the tissue protective properties of TPO. Dr. Bakers discovery is licensed to Cardiopoietis, a Wisconsin LLC, formed to develop drugs for the treatment of heart attacks.

TPO is a hormone which is naturally produced by the liver and kidney. Dr. Bakers investigative team had previously shown that erythropoietin, a protein and pharmaceutical currently in clinical use to treat anemia in end-stage kidney disease, protects the rat heart against injury during a heart attack. They found that although erythropoietin and TPO have separate functional roles, there were similarities in the structures of the two proteins that suggested TPO may have protective properties similar to erythropoietin.


'/>"/>

Contact: Toranj Marphetia
toranj@mcw.edu
414-456-4744
Medical College of Wisconsin
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Draining away brains toxic protein to stop Alzheimers
2. Penn study finds pro-death proteins required to regulate healthy immune function
3. New prion protein discovered by Canadian scientists may offer insight into mad cow disease
4. Emory researchers identify signaling protein for multiple myeloma
5. Human C-reactive protein regulates myeloma tumor cell growth and survival
6. Lowering Blood Protein Wont Help Kidney Patients
7. Blood protein detects lung cancer, even at earliest stage
8. Natural Protein Could Help Spot, Treat Liver Cancer
9. Heat shock proteins are co-opted for cancer
10. How adhesive protein causes malaria
11. Loss of gene leads to protein splicing and buildup of toxic proteins in neurons

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)...ire-USNewswire/ -- Considered a highly risky and c...solid organ transplantation is now a life-saving m...n and women who gathered at the Winspear Opera Hou...m medical centers around the world to celebrate th...nstitute (BRTI), one of the pioneers of solid orga...
(Date:11/27/2009)...ov. 27 Shamir Optical In...ng provider of innovative products and technology ...t its board of directors had declared a dividend d...on (approximately NIS 37.62 million based on the N... or approximately US$ 0.609 (approximately NIS 2.3...
(Date:11/27/2009)... Nov. 27 Allrecipes.com , the w...ving traffic numbers, with more than 2.8 million v...lear picture of what was served on the biggest foo...al in 2009 weighed in at 2,225 calories per servin...cording to the Allrecipes site, Sweet Potato Pie ...
(Date:11/27/2009)...interactive anatomy education apps from Modality a... sciences learning opportunities for iPhone and iP...cus) November 27, 2009 -- Modality, Inc. and Lip...f Wolters Kluwer Health, today announced the avail... App Store. Clemente’s Anatomy, Rohen’...
(Date:11/26/2009)...thiomolybdate (TM) has been shown in studies to be...isease caused by an overload of copper, and certai...tle, however, is known about how the drug works at...western University researchers now has provided an...of TM bound to copper-loaded metallochaperones. Th...
Breaking Medicine News(10 mins):Health News:Organ Transplant Pioneers Celebrate Baylor Regional Transplant Institute's 25th Anniversary 2Health News:Organ Transplant Pioneers Celebrate Baylor Regional Transplant Institute's 25th Anniversary 3Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 2Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 3Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 2Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 3Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 4Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 2Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 4Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 5Health News:Research sheds light on workings of anti-cancer drug 2Health News:Research sheds light on workings of anti-cancer drug 3
...H, Minn., April 29 ev3 Inc. (Nasdaq:,EVVV) today ...ef executive,officer, is scheduled to present at t...uesday, May 13, 2008 at 4:00 p.m. PT (7:00 p.m. ET...t, go to the investors, section of the ev3 Web sit...
...tate contracts EDS interChange System to manage na...program, New IT solution will administer payments ...th records, help state identify health trends and ...ents, has been awarded a,seven-year, $391 million ...
...rphy Appointed as New Senior Vice President of Con... Pharsight,Corporation (Nasdaq: PHST ), a leadin...regulatory services for optimizing clinical drug,d...es. In this role, Dr. Murphy will lead the Company...
...LE, Tenn., April 29 With an 89% initial success,r...ggressive cancers, a,Nashville-based treatment is ...cording to NeoPlas Innovation Director of Research...en effective,for malignant melanoma, as well as pa...
...rence Call to Occur on Wednesday, April 30 at 2 p....on, Inc.,(Nasdaq: VRML ), a molecular diagnostics... address the need for improved detection of periph...nce will take place on Wednesday, April 30 at 2 p....
...TOWNSHIP, Michigan, April 28 Nearly ten years,aft... three years after FDA,approval, LASIK surgery is ...ered complications or experienced poor outcomes., ...n, to pain, to severe activity-limiting visual hal...
Other Medicine News:Health News:EDS Returns to Georgia With $391 Million Medicaid Win 2Health News:EDS Returns to Georgia With $391 Million Medicaid Win 3Health News:Pharsight Strengthens Senior Management Team 2Health News:Pharsight Strengthens Senior Management Team 3Health News:New Treatment Offers Hope for Beating Aggressive Cancers 2Health News:Vermillion to Host Live Roundtable Discussion With Lead Investigator of its Peripheral Artery Disease Diagnostic Test Program 2Health News:Vermillion to Host Live Roundtable Discussion With Lead Investigator of its Peripheral Artery Disease Diagnostic Test Program 3Health News:Vermillion to Host Live Roundtable Discussion With Lead Investigator of its Peripheral Artery Disease Diagnostic Test Program 4Health News:FDA Examines LASIK Surgery Complications 2
(Date:11/25/2009)...RNewswire-FirstCall/ -- ERT (Nasdaq: ERES ), anno...any,s President and CEO, and Keith Schneck, the Co...duled to present at the 21st Annual Piper Jaffray ...1, 2009 in New York City, New York. ,, Interest... the Company,s corporate website at http://www.er...
(Date:11/25/2009)...ire/ -- BioTrends Research Group, Inc. released Wa...rt, the first in a multi-phase syndicated market r...tho-Biotech,s Stelara, from product launch through...of the report provides quantitative information fr...ation from a subset of 20. The reports assess tri...
(Date:11/25/2009)... 25 For many of the mill... 27 million living with untreated hearing loss , ...logist Cindy Beyer. ,, Dr. Beyer, senior vice p...s largest hearing care and hearing aids companie..., frustration, and social isolation, "which can ea...
Breaking Medicine Technology:ERT to Present at the 21st Annual Piper Jaffray Health Care Conference on December 1, 2009 2Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High 2For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 2For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 3MAQUET Cardiovascular Awarded New Contract by Novation 51197 1MAQUET Cardiovascular Awarded New Contract by Novation 51197 2Shanghai ChemPartner and Agios Expand Integrated Drug Discovery Research Collaboration 12954 1Shanghai ChemPartner and Agios Expand Integrated Drug Discovery Research Collaboration 12954 2IDEV Technologies Names Veteran Medical Device Executive Rick Anderson Chairman of the Board of Directors 12952 1IDEV Technologies Names Veteran Medical Device Executive Rick Anderson Chairman of the Board of Directors 12952 2
...ADELPHIA, May 22 Shire plc (LSE: SHP, Nasdaq: ...ompany, announced results of a study showing that ... (lisdexamfetamine dimesylate) CII with the proton... X 2), did not alter the median time it took for m...be reached in the subjects evaluated. In the same...
... ALTO, Calif., May 21 Telik, Inc. (Nasdaq: TELK...mized clinical study of canfosfamide (TELCYTA(R), ...xorubicin (PLD) vs. PLD will be presented at the 4...ical Oncology (ASCO) which will be held from May 2...esentation are as follows: , , , -- Abs...
Other Medicine Technology:New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 2New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 3New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 4New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 5New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 6New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 7New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 8
Curved Dressing Forceps With Serrations
Troutman-Barraquer Corneal Utility Forceps, Colibri Style - 0.5 mm
Catalano Corneal Scleral Forceps
Troutman-Barraquer Corneal Utility Forceps, Colibri Style
Medicine Products: